<DOC>
	<DOC>NCT00308581</DOC>
	<brief_summary>To assess the clinical efficacy of subcutaneous (sc) certolizumab pegol administration over 26 weeks in patients suffering from Crohn's Disease (CD) and previously treated with infliximab</brief_summary>
	<brief_title>Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Subjects with Crohn's Disease Previous treatment failure to Infliximab (intolerance and/or no response) Obstructive intestinal strictures Recent bowel resection Proctocolectomy or total colectomy Current total parenteral nutrition Short bowel syndrome All concomitant diseases or pathological conditions that could interfere with Crohn's disease assessment or to be harmful for the well being of the patient Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Crohn's Disease</keyword>
	<keyword>Certolizumab pegol</keyword>
</DOC>